Excerpt from Minimal-Change DiseaseSynonyms, Key Words, and Related Terms: MCD, idiopathic nephrotic syndrome of childhood, lipoid nephrosis, minimal-change nephropathy, minimal-change nephrotic syndrome, MCNS, nil disease, steroid-sensitive nephrotic syndrome Please click here to view the full topic text: Minimal-Change DiseaseBackgroundMinimal-change disease (MCD), also known as lipoid nephrosis or nil disease, is the most common single form of nephrotic syndrome in children. It refers to a histopathologic lesion in the glomerulus that almost always is associated with nephrotic syndrome. It typically is a disease of childhood, but it also can occur in adults. PathophysiologyIt is postulated that MCD is a disorder of T cells, which release a cytokine that injures the glomerular epithelial foot processes. This, in turn, leads to a decreased synthesis of polyanions. The polyanions constitute the normal charge barrier to the filtration of macromolecules, such as albumin. When the polyanions are damaged, leakage of albumin follows. The identity of this circulating permeability factor is uncertain, although it is postulated that it may be hemopexin. Some of the cytokines that have been studied in MCD are interleukin-12 (IL-12) and interleukin-4 (IL-4). IL-12 levels have been found to be elevated in peripheral blood monocytes during the active phase and normalized during remission. Interleukin-18 (IL-18) can synergize with IL-12 to selectively increase the production of vascular permeability factor from T cells. In addition, levels of IL-4 and CD23 (a receptor for immunoglobulin E) have been found to be elevated in peripheral blood lymphocytes. Synaptopodin is a proline-rich protein intimately associated with actin microfilaments present in the foot processes of podocytes. Greater synaptopodin expression in podocytes is associated with a significantly better response to steroid therapy. On the other hand, the expression of synaptopodin does not predict progression of MCD or diffuse mesangial hypercellularity to focal segmental glomerulosclerosis (FSGS). Thus, this marker could be used in the future to help determine appropriate therapy. Interleukin-13 (IL-13) has been implicated in the pathogenesis of MCD. In a study on Singapore Chinese children, it was shown that IL-13 genetic polymorphisms correlate with the long-term outcome of MCD. In patients who develop acute renal failure, endothelin 1 expression is greater in the glomeruli, vessels, and tubules than in the nonacute renal failure group. The glomerular epithelial cells (podocytes) and the slit diaphragm connecting the podocyte foot processes play a primary role in the development of proteinuria. Nephrin is a major component of the slit diaphragm. The slit diaphragm is often missing in MC nephrotic syndrome (MCD) kidneys. The role of nephrin and the slit diaphragm in MCD is not known. However, genetic variants of a glomerular filter protein may play a role in some patients with MCD. Lack of glomerular dysferlin expression has been recently associated with minimal change nephropathy in a patient with limb-girdle muscular dystrophy type 2B. Two of the three patients with this disease had increased microalbuminuria. Although there have been a multitude of studies recently published, the mechanism by which T cells increase glomerular permeability has remained unproven. FrequencyUnited StatesIn preadolescents, minimal-change nephrotic syndrome (MCNS) makes up 85-95% of all causes of nephrotic syndrome. In adolescents and young adults, the prevalence is 50%. In the population older than 40 years, it is found in 20-25% of cases with nephrotic syndrome. Incidence is 2-7 new cases per 100,000 children, and the prevalence is 15 cases per 100,000 children. Mortality/MorbidityVery few patients progress to end-stage renal disease. These patients are those who have FSGS that has been misdiagnosed as MCD.
Race
Sex
Age
Please click here to view the full topic text: Minimal-Change Disease |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |